Literature DB >> 12680826

The seroprevalence of Helicobacter pylori infection in patients with obstructive sleep apnoea: a preliminary study.

M Unal1, L Oztürk, C Oztürk, A Kabal.   

Abstract

We investigated the seroprevalence of Helicobacter pylori in patients with obstructive sleep apnoea. A prospective clinical study consisting of 19 patients, aged 23-72 years with confirmed obstructive sleep apnoea by overnight polysomnography, and 36 control subjects, aged 25-61 years with no history of obstructive sleep apnoea and gastroesophageal reflux complaints, was conducted. Titres of serum H. pylori IgG antibody were assayed by a serum enzyme-linked immunoabsorbant assay. The difference between the study and control groups was analysed by chi-squared test. Seventeen of the 19 patients (89.5%) were found to be H. pylori positive. However, 21 of the 36 control subjects (58.3%) were H. pylori positive. The seropositivity of H. pylori in obstructive sleep apnoea patients was found to be significantly higher than the control group (P = 0.017). The result of our study shows that there is a high association between H. pylori infection and obstructive sleep apnoea. This data may be important for future treatment strategies of the disease.

Entities:  

Mesh:

Year:  2003        PMID: 12680826     DOI: 10.1046/j.1365-2273.2003.00672.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  2 in total

1.  Presence of different genotypes of Helicobacter pylori in patients with chronic tonsillitis and sleep apnoea syndrome.

Authors:  Eva Nártová; Jaroslav Kraus; Emil Pavlík; Petr Lukeš; Rami Katra; Jan Plzák; Libuše Kolářová; Ivan Sterzl; Jan Betka; Jaromír Astl
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-07-18       Impact factor: 2.503

2.  Effect of Helicobacter pylori-Associated Chronic Gastritis on Autonomous Activity and Sleep Quality in Mice.

Authors:  Haihua Liu; Wenlong Zheng; Ling Zhang; Tangtang Lin; Yang Tang; Ling Hu
Journal:  Front Pharmacol       Date:  2022-02-04       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.